TREATMENT COM AI INC - TREIF STOCK NEWS

Treatment.com AI Inc. announces the success of its AI medical information support platform in the 'Objective Structured Clinical Examination' with a 92% success rate. The platform was used by a non-medical college student who successfully diagnosed various diseases, showcasing the AI's accuracy and potential in medical education and clinical support.

Treatment.com AI Inc. announces the successful closing of a non-brokered private placement, raising $2,908,200. The Company issued 6,295,500 special warrants and 975,000 units at $0.40 each. Each special warrant will convert into one unit upon meeting certain conditions. CEO Dr. Essam Hamza is optimistic about the funds aiding the company's growth plans. The Company paid finder's fees and issued broker warrants, intending to utilize the proceeds for working capital. The securities issued are subject to statutory hold periods and are not listed on any stock exchange.

Treatment.com AI Inc. announces key leadership appointments and the expansion of the Global Library of Medicine, reaching over 1,000 diseases. The platform supports healthcare in Nairobi, Kenya, showcasing the company's commitment to growth and community impact.

Treatment.com AI Inc. (TREIF) appoints Mr. David Worner as Chief Financial Officer, effective February 5, 2024. Mr. Worner brings extensive experience in accounting, mergers, acquisitions, and public offerings. The company is entering a phase of rapid growth and commercialization.

Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) is advancing healthcare with its newly launched Treatment Digital Health App, gaining five-star ratings on both Apple and Google platforms. Users, including medical professionals, praise its comprehensive and accurate health assessments. The app is powered by a robust AI-driven Global Library of Medicine, designed to deliver innovative health insights. CEO John Fraser emphasizes the company's commitment to support the medical community and enhance patient care through technology.

Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) announced a non-brokered private placement to raise up to $1,250,000 through unsecured convertible debentures. Each debenture will have an 8% interest rate, maturing in 36 months, and is convertible into units at a price of $0.41. Investors will receive interest payments monthly, with the option to be paid in company units. The funds will be used for general working capital. The units issued upon conversion will be subject to a 12-month hold period.

Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) launched its Treatment Digital Health App on the Google Play Store, expanding access to its innovative AI-driven healthcare technology. The app, initially available on the Apple App Store, is designed to assist users in making informed health decisions with advanced medical knowledge. The launch aligns with the increasing demand for credible health information, particularly during the COVID era. CEO John Fraser and Chief Strategy Officer Dr. Paul A. Markham emphasized the app's groundbreaking capabilities compared to typical online health searches.

Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) has officially launched the Treatment Digital Health App, now available on the Apple App Store. This innovative app utilizes a next-generation AI platform, offering users advanced symptom assessment tools built by a team of medical professionals and engineers. The app's technology is designed to provide accurate health insights, leveraging the Global Library of Medicine (GLM) for up-to-date medical information. The CEO emphasizes the app's role in enhancing healthcare decision-making during the pandemic, aiming for improved individual health outcomes.

Treatment.com International (CSE: TRUE, OTC: TREIF) has announced a research project agreement with the University of Minnesota to add over 220 dermatologic diseases to its AI engine, the Global Library of Medicine (GLM). This collaboration aims to enhance the accuracy of the GLM, supporting the upcoming Treatment Mobile app release. According to Treatment's Chief Medical Officer, the partnership will leverage the University’s expertise to improve skin disease descriptions, thereby aiming to better health outcomes globally. The Treatment Mobile app and intelligent assistant are set to launch in selected North American clinics in 2022.